There aren't a lot of great med-tech growth stories these days, and many of those are already quite expensive. Novadaq Technologies (NVDQ)
is hardly cheap at almost 22 times sales, but this company is very
early in its product launch life and could see revenue grow from about
$25 million over the trailing 12 months to perhaps $1 billion down the
road.
With an affordable, safe, easy-to-use diagnostic system that
delivers very real benefits in terms of lower complication rates and
costs, Novadaq has an impressive opportunity as well as strong partners
like LifeCell and Intuitive Surgical (ISRG)
to help them realize those opportunities. I think it's relatively easy
to argue that Novadaq is worth about $18 per share today, and seeing
upside beyond $21 is not too challenging.
Please continue to the full article here:
Red-Hot Novadaq Shows There's Green In Being Green
No comments:
Post a Comment